EIP Pharma closes financing for new indications for former Vertex drug

EIP Pharma, a central nervous system-focused therapeutics company, announced the successful completion of $11.2 million in new private funding to explore the use of an investigational drug as a treatment for dementia with Lewy bodies and for the cognitive deficits in Huntington ' s disease.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news